Clinical Trial

A Study of Docetaxel for Injection (Albumin-bound) and SG001 in Combination With Cisplatin and Simultaneous Radiotherapy for Locally Advanced Unresectable Esophageal Squamous Carcinoma.

Not Yet Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
The study is a multicenter, open-label, phase Ib/II study to evaluate the efficacy and safety of docetaxel for injection (albumin-bound) (HB1801) and SG001 in combination with cisplatin and simultaneous radiotherapy versus paclitaxel in combination with cisplatin and simultaneous radiotherapy for locally advanced unresectable esophageal squamous carcinoma.
Trial Details
NCT Number NCT06136988
Lead Sponsor CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Conditions Locally Advanced Unresectable Esophageal Squamous Carcinoma
Enrollment 129 participants
Start Date 2023-12
Primary Completion 2027-04 (estimated)
Study Completion 2028-04 (estimated)
Updated on ClinicalTrials.gov 2023-11-18